Tata Vs Mistry

The patriarch of the over 155-year-old construction empire held an 18.4 per cent stake in Tata Sons

The genesis of the dispute can be traced to the removal of Mistry as executive chairman of Tata Sons in 2016

Mistry had succeeded Ratan Tata as the chairman of TSPL in 2012 but was ousted four years later

Has approached foreign banks for a Rs 5,000-crore bridge loan

Minority shareholders rights to get impacted, says review petition in SC

The legal fracas is just posturing by SP Group to get a better valuation of its stake in the conglomerate, says a lawyer

In its March 26 judgement, Supreme Court had ruled in favour of the Tata Group

In its March 26 verdict, the court had ruled in favour of the Tata group

The Supreme Court's observations in the Tata-Mistry case has raised questions about the fiduciary duties of nominee directors

Here's a selection of Business Standard opinion pieces for the day

They stand vindicated in the Mistry saga, but what is legally sound may not conform to the best standards of governance

Experts explain the distinction between the rights of small and minority shareholders in public-listed and private companies

Mistry said that he is disappointed by the Supreme Court verdict on his battle with Tata Sons

Now the Mistrys are not getting even a board seat on Tata Sons, and the court has left it to both parties to negotiate the exit price of Mistrys

Tata Group may offer an exit to Mistry family from Tata Sons on the basis of valuation chartered accountant Y H Malegam put in 2016.

Here are the top business headlines on Tuesday morning

There's room in India for a Tata super-app to compete with Mukesh Ambani's Reliance Industries Ltd

The price of the AstraZeneca vaccine - the one sold the most globally- varies from $2 to $6 per dose. India has got this vaccine at $2.06 per dose, the cheapest in the world. Read today's top news

The court has made it clear that Mistry Group is not a small shareholder and a board seat cannot be allotted to it contractually or by law

Another legal battle over stake valuation must be avoided